Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 4Gynecologic 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 218Fluorouracil 142Oxaliplatin 132Capecitabine 122pembrolizumab 113Irinotecan 110Leucovorin 104Bevacizumab 98Nivolumab 80Cisplatin 80130-nm albumin-bound paclitaxel 80Cetuximab 79Radiotherapy 78Albumin-Bound Paclitaxel 59Sorafenib 56Paclitaxel 53Cyclophosphamide 50Carboplatin 47Magnetic Resonance Spectroscopy 44Specimen Handling 39Docetaxel 37Taxes 36fludarabine 34Radiation 34durvalumab 33Ipilimumab 33Erlotinib Hydrochloride 33Biopsy 33Radiosurgery 27Folfox protocol 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Monatide (IMS 3015) × Gastrointestinal × Clear all
NCT06218511 2025-12-22

A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)

National Cancer Institute, Naples

Phase 1 Active not recruiting
10 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡